Show simple item record

dc.contributor.authorTrevino, CE
dc.contributor.authorRounds, JC
dc.contributor.authorCharen, K
dc.contributor.authorShubeck, L
dc.contributor.authorHipp, HS
dc.contributor.authorSpencer, JB
dc.contributor.authorJohnston, HR
dc.contributor.authorCutler, DJ
dc.contributor.authorZwick, ME
dc.contributor.authorEpstein, MP
dc.contributor.authorMurray, A
dc.contributor.authorMacpherson, JN
dc.contributor.authorMila, M
dc.contributor.authorRodriguez-Revenga, L
dc.contributor.authorBerry-Kravis, E
dc.contributor.authorHall, DA
dc.contributor.authorLeehey, MA
dc.contributor.authorLiu, Y
dc.contributor.authorWelt, C
dc.contributor.authorWarren, ST
dc.contributor.authorSherman, SL
dc.contributor.authorJin, P
dc.contributor.authorAllen, EG
dc.date.accessioned2021-10-25T07:48:06Z
dc.date.issued2021-05-18
dc.description.abstractObjective: To identify modifying genes that explains the risk of fragile X-associated primary ovarian insufficiency (FXPOI). Design: Gene-based, case/control association study, followed by a functional screen of highly ranked genes using a Drosophila model. Setting: Participants were recruited from academic and clinical settings. Patient(s): Women with a premutation (PM) who experienced FXPOI at the age of 35 years or younger (n = 63) and women with a PM who experienced menopause at the age of 50 years or older (n = 51) provided clinical information and a deoxyribonucleic acid sample for whole genome sequencing. The functional screen was on the basis of Drosophila TRiP lines. Intervention(s): Clinical information and a DNA sample were collected for whole genome sequencing. Main Outcome Measures: A polygenic risk score derived from common variants associated with natural age at menopause was calculated and associated with the risk of FXPOI. Genes associated with the risk of FXPOI were identified on the basis of the P-value from gene-based association test and an altered level of fecundity when knocked down in the Drosophila PM model. Results: The polygenic risk score on the basis of common variants associated with natural age at menopause explained approximately 8% of the variance in the risk of FXPOI. Further, SUMO1 and KRR1 were identified as possible modifying genes associated with the risk of FXPOI on the basis of an untargeted gene analysis of rare variants. Conclusions: In addition to the large genetic effect of a PM on ovarian function, the additive effects of common variants associated with natural age at menopause and the effect of rare modifying variants appear to play a role in FXPOI risk.en_GB
dc.description.sponsorshipEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)en_GB
dc.description.sponsorshipFundacion Merck Saluden_GB
dc.identifier.citationVol. 116 (3), pp. 843 - 854en_GB
dc.identifier.doi10.1016/j.fertnstert.2021.04.021
dc.identifier.grantnumberR01 HD099487en_GB
dc.identifier.urihttp://hdl.handle.net/10871/127569
dc.language.isoenen_GB
dc.publisherElsevier / American Society for Reproductive Medicineen_GB
dc.rights©2021 The Authors. Published by Elsevier Inc. on behalf of the American Society for Reproductive Medicine. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).en_GB
dc.subjectFragile X-associated disordersen_GB
dc.subjectFXPOIen_GB
dc.subjectKRR1en_GB
dc.subjectprimary ovarian insufficiencyen_GB
dc.subjectSUMO1en_GB
dc.titleIdentifying susceptibility genes for primary ovarian insufficiency on the high-risk genetic background of a fragile X premutationen_GB
dc.typeArticleen_GB
dc.date.available2021-10-25T07:48:06Z
dc.identifier.issn0015-0282
dc.descriptionThis is the final version. Available on open access from Elsevier via the DOI in this recorden_GB
dc.identifier.journalFertility and Sterilityen_GB
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en_GB
dcterms.dateAccepted2021-04-21
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2021-05-18
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2021-10-25T07:42:41Z
refterms.versionFCDVoR
refterms.dateFOA2021-10-25T07:48:12Z
refterms.panelAen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record

©2021 The Authors. Published by Elsevier Inc. on behalf of the American Society for Reproductive Medicine. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Except where otherwise noted, this item's licence is described as ©2021 The Authors. Published by Elsevier Inc. on behalf of the American Society for Reproductive Medicine. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).